01 Genomic surveillance and rapid testing are transforming virus detection The virology market is moving toward faster, more connected methods for detecting and tracking viral diseases. Laboratories increasingly use real-time PCR, next-generation sequencing, multiplex panels, wastewater monitoring, and portable diagnostic systems. Genomic surveillance helps health agencies identify new variants, trace transmission, and guide vaccines or antiviral use. Demand is also growing for tests that detect several respiratory viruses from one sample, reducing diagnosis time and unnecessary treatment. Digital reporting platforms are connecting laboratories with hospitals and public health networks. Research is expanding beyond human disease to include viruses affecting livestock and wildlife, reflecting wider adoption of the One Health approach to outbreak preparedness. Aug 2026 Global health monitoring confirmed that several mpox virus clades continued causing localized and extended outbreaks across multiple regions.
01 Recurring viral outbreaks increase testing and research demand The continued emergence and spread of viral diseases remain the main drivers of virology products and services. Mpox, influenza, COVID-19, dengue, hepatitis, HIV, and animal-origin viruses require ongoing surveillance, laboratory confirmation, treatment research, and vaccination programs. International travel and changing climate conditions can help infections reach new locations, increasing the need for flexible diagnostic capacity. Governments are strengthening laboratory networks and emergency preparedness after weaknesses revealed during previous outbreaks. Hospitals also require rapid tests to distinguish viral infections with similar symptoms. Growing awareness of early diagnosis, infection control, and routine viral-load monitoring further supports demand for reagents, instruments, sequencing services, antiviral medicines, and specialized laboratory infrastructure.
01 High laboratory costs limit access in lower-resource regions Modern virology testing often requires expensive instruments, specialized reagents, cold-chain logistics, trained personnel, and controlled laboratory environments. Many low-income and remote areas lack these resources, causing delayed diagnosis and incomplete disease reporting. Molecular and sequencing tests may also remain unaffordable for routine use when public funding is limited. Regulatory approval can take time because manufacturers must demonstrate accuracy, safety, and reliable performance across different variants and sample types. Demand may fall quickly after an outbreak declines, creating uncertain returns on production capacity. Biosafety requirements add further costs when laboratories handle dangerous viruses. Import dependence and reagent shortages can also interrupt testing during sudden international emergencies.
01 Decentralized diagnostics and One Health surveillance offer growth Affordable point-of-care tests create an important opportunity to expand viral diagnosis beyond centralized laboratories. One Health programs offer further potential by combining human, animal, and environmental surveillance to identify dangerous viruses before widespread transmission occurs. Wastewater sequencing can provide early community-level signals without testing every individual. Additional opportunities exist in antiviral discovery, vaccine monitoring, laboratory automation, bioinformatics, and regional manufacturing of diagnostic reagents to reduce import dependence.
01 Rapid viral evolution can reduce test and treatment effectiveness Viruses can mutate, recombine, and cross between animal and human populations, making long-term disease control difficult. Genetic changes may reduce diagnostic sensitivity, alter transmission, or weaken the effectiveness of vaccines and antiviral medicines. Laboratories must continually update primers, reference materials, databases, and testing procedures. Uneven surveillance creates another challenge because outbreaks can spread before countries detect and report them. Sharing viral sequences and patient data also raises privacy, ownership, and biosecurity concerns. Misinformation may reduce public participation in testing or vaccination programs. Researchers must respond quickly while maintaining scientific quality, ethical review, and regulatory compliance. Sustained funding is difficult once public attention moves away from an outbreak.
February 2024- Start-up representatives from the Research Innovation Network Kerala (RINK) of the Kerala Startup Mission (KSUM) visited the Institute of Advanced Virology (IAV) at the Life Sciences Park. This visit aimed to help start-ups explore opportunities for incubation and co-development of products and services with the institute.
October 2023- Gilead Sciences, Inc. disclosed recent findings from its virology research and development initiatives, which will be showcased at IDWeek 2023, taking place in Boston from October 11-15. The recent findings exemplify the company's continuous endeavors to tackle the unfulfilled medical requirements of individuals and communities impacted by HIV and COVID-19.